Precision Therapy of Recurrent Breast Cancer through Targeting Different Malignant Tumor Cells with a HER2/CD44‐Targeted Hydrogel Nanobot
Small · 2023
DOI: 10.1002/smll.202301043 ↗Kurz gefasst
Fachartikel in der Zeitschrift Small, 2023. Verfasst von Juan Chen und 13 weiteren Autor:innen. Beteiligte Einrichtung: Engineering Research Center of Cell & Therapeutic Antibody, Ministry of Education, and School of Pharmacy, Shanghai Jiao Tong University, 800 Dongchu…. Hauptthemen laut MEDLINE: Breast Neoplasms. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Shanghai Jiao Tong University.
Abstract (Originalsprache)
Heterogeneity and drug resistance of tumor cells are the leading causes of incurability and poor survival for patients with recurrent breast cancer. In order to accurately deliver the biological anticancer drugs to different subtypes of malignant tumor cells for omnidirectional targeted treatment of recurrent breast cancer, a distinct design is demonstrated by embedding liposome‐based nanocomplexes containing pro‐apoptotic peptide and survivin siRNA drugs (LPR) into Herceptin/hyaluronic acid cross‐linked nanohydrogels (Herceptin‐HA) to fabricate a HER2/CD44‐targeted hydrogel nanobot (named as ALPR). ALPR delivered cargoes to the cells overexpressing CD44 and HER2, followed by Herceptin‐HA biodegradation, subsequently, the exposed lipid component containing DOPE fused with the endosomal membrane and released peptide and siRNA into the cytoplasm. These experiments indicated that ALPR can specifically deliver Herceptin, peptide, and siRNA drugs to HER2‐positive SKBR‐3, triple‐negative MDA‐MB‐231, and HER2‐negative drug‐resistant MCF‐7 human breast cancer cells. ALPR completely inhibited the growth of heterogeneous breast tumors via multichannel synergistic effects: disrupting mitochondria, downregulating the survivin gene, and blocking HER2 receptors on the surface of HER2‐positive cells. The present design overcomes the chemical drug resistance and opens a feasible route for the combinative treatment of recurrent breast cancer, even other solid tumors, utilizing different kinds of biological drugs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Engineering Research Center of Cell & Therapeutic Antibody, Ministry of Education, and School of Pharmacy, Shanghai Jiao Tong University, 800 Dongchuan Road, Shanghai, 200240, China.
- Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, 600 Yi-Shan Road, Shanghai, 200233, China.
- The International Peace Maternity and Child Health Hospital, School of Medicine, Shanghai Jiao Tong University, 910 Hengshan Road, Shanghai, 200030, China.
- Department of Obstetrics and Gynecology, Shanghai General Hospital affiliated with Shanghai Jiao Tong University, 100 Haining Road, Shanghai, 200080, China.
ORCID-Profile: Zixiu Du
Förderung
- National Natural Science Foundation of China
- Shanghai Jiao Tong University
Zitieren
APA
Chen, J., Li, J., Sun, X., Lu, H., Liu, K., Li, Z., Guan, J., Song, H., Wei, W., Ge, Y., Fan, Q., Bao, W., Ma, B., & Du, Z. (2023). Precision Therapy of Recurrent Breast Cancer through Targeting Different Malignant Tumor Cells with a HER2/CD44‐Targeted Hydrogel Nanobot. Small. https://doi.org/10.1002/smll.202301043
Vancouver
Chen J, Li J, Sun X, Lu H, Liu K, Li Z, et al. Precision Therapy of Recurrent Breast Cancer through Targeting Different Malignant Tumor Cells with a HER2/CD44‐Targeted Hydrogel Nanobot. Small. 2023. doi:10.1002/smll.202301043
BibTeX
@article{Chen2023,
author = {Chen, Juan and Li, Jinjin and Sun, Xiaolu and Lu, Huixia and Liu, Kuai and Li, Zhenbo and Guan, Jianyue and Song, Huiling and Wei, Wei and Ge, Yanhong and Fan, Qiong and Bao, Wei and Ma, Buyong and Du, Zixiu},
title = {Precision Therapy of Recurrent Breast Cancer through Targeting Different Malignant Tumor Cells with a HER2/CD44‐Targeted Hydrogel Nanobot},
journal = {Small},
year = {2023},
doi = {10.1002/smll.202301043}
}
EUVIMED